SEC Form 4 · accession 0001140361-17-043871
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Mayleben
Director
Period of report
Nov 22, 2017
Accepted (ET)
Nov 27, 2017 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 22, 2017 | M | 3,000 | $20.91 | A | 13,000 | D | |
| Common StockF1,F2 | Nov 22, 2017 | S | 3,000 | $75.8542 | D | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F3 | $20.91 | Nov 22, 2017 | M | 3,000 | D | — | Jul 27, 2025 | Common Stock | 3,000 | 12,625 | D |
Explanation of responses
- F1Represents the aggregate of sales effected on the same day at different prices.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $75.76 to $75.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3The stock option vests and becomes exercisable as to 1/3 of the shares subject to the option on the one-year anniversary of the grant date, and thereafter vests as to an additional 1/3 of the shares annually.